These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 27818728)
1. Evaluation of Haemagglutinin Content by RP-HPLC to Generate Pandemic Influenza Vaccine. Kang H; Roh HS; Song H; Lee K; Chung ST; Ban SJ; Mo IP; An BS; Ahn CY Toxicol Res; 2016 Oct; 32(4):269-274. PubMed ID: 27818728 [TBL] [Abstract][Full Text] [Related]
2. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Lorbetskie B; Wang J; Gravel C; Allen C; Walsh M; Rinfret A; Li X; Girard M Vaccine; 2011 Apr; 29(18):3377-89. PubMed ID: 21397719 [TBL] [Abstract][Full Text] [Related]
3. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Kapteyn JC; Porre AM; de Rond EJ; Hessels WB; Tijms MA; Kessen H; Slotboom AM; Oerlemans MA; Smit D; van der Linden J; Schoen P; Thus JL Vaccine; 2009 Feb; 27(9):1468-77. PubMed ID: 19110022 [TBL] [Abstract][Full Text] [Related]
4. A hemagglutinin quantification method for development of an influenza pandemic vaccine using size exclusion high performance liquid chromatography. Roh HS; Song HM; Yun BR; Kang HK; Choi KS; Park YJ; Kim DS; Kim SH; Mo IP; An BS; Ahn CY Mol Med Rep; 2015 Apr; 11(4):2819-24. PubMed ID: 25482872 [TBL] [Abstract][Full Text] [Related]
5. Conformationally selective biophysical assay for influenza vaccine potency determination. Wen Y; Han L; Palladino G; Ferrari A; Xie Y; Carfi A; Dormitzer PR; Settembre EC Vaccine; 2015 Oct; 33(41):5342-5349. PubMed ID: 26348403 [TBL] [Abstract][Full Text] [Related]
6. HA1 (Hemagglutinin) quantitation for influenza A H1N1 and H3N2 high yield reassortant vaccine candidate seed viruses by RP-UPLC. Fulvini AA; Tuteja A; Le J; Pokorny BA; Silverman J; Bucher D Vaccine; 2021 Jan; 39(3):545-553. PubMed ID: 33341306 [TBL] [Abstract][Full Text] [Related]
7. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings. Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389 [TBL] [Abstract][Full Text] [Related]
8. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity. Wen Y; Palladino G; Xie Y; Ferrari A; Settembre EC Vaccine; 2018 May; 36(21):3010-3017. PubMed ID: 29680201 [TBL] [Abstract][Full Text] [Related]
9. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687 [TBL] [Abstract][Full Text] [Related]
10. An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines. Bodle J; Vandenberg K; Laurie K; Barr IG; Zhang Y; Rockman S Front Immunol; 2023; 14():1147028. PubMed ID: 37033922 [TBL] [Abstract][Full Text] [Related]
11. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Kapteyn JC; Saidi MD; Dijkstra R; Kars C; Tjon JC; Weverling GJ; de Vocht ML; Kompier R; van Montfort BA; Guichoux JY; Goudsmit J; Lagerwerf FM Vaccine; 2006 Apr; 24(16):3137-44. PubMed ID: 16490287 [TBL] [Abstract][Full Text] [Related]
13. Critical review of current and emerging quantification methods for the development of influenza vaccine candidates. Manceur AP; Kamen AA Vaccine; 2015 Nov; 33(44):5913-9. PubMed ID: 26271833 [TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines. Schmeisser F; Vasudevan A; Soto J; Kumar A; Williams O; Weir JP Influenza Other Respir Viruses; 2014 Sep; 8(5):587-95. PubMed ID: 25087462 [TBL] [Abstract][Full Text] [Related]
15. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976 [TBL] [Abstract][Full Text] [Related]
16. Reference antigen-free and antibody-free LTD-IDMS assay for influenza H7N9 vaccine in vitro potency determination. Morgenstern K; Xie Y; Palladino G; Barr JR; Settembre EC; Williams TL; Wen Y Vaccine; 2018 Oct; 36(41):6144-6151. PubMed ID: 30194004 [TBL] [Abstract][Full Text] [Related]
17. A latex agglutination assay to quantify the amount of hemagglutinin protein in adjuvanted low-dose influenza monovalent vaccines. Buffin S; Ikhelef N; Prudent J; Dubayle J; Nougarede N; Varenne MP; Moste C; Legastelois I J Virol Methods; 2018 Jan; 251():46-53. PubMed ID: 29030070 [TBL] [Abstract][Full Text] [Related]
18. Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion. Bodle J; Verity EE; Ong C; Vandenberg K; Shaw R; Barr IG; Rockman S Influenza Other Respir Viruses; 2013 Mar; 7(2):191-200. PubMed ID: 22583601 [TBL] [Abstract][Full Text] [Related]
19. Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay. Lorbetskie B; Cunningham AM; Lemieux M; Durno L; Farnsworth A; Wang J; Li C; Li X; Gilbert M; Sauvé S; Girard M Anal Chem; 2019 Jul; 91(14):8908-8917. PubMed ID: 31251585 [TBL] [Abstract][Full Text] [Related]
20. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency. Khurana S; King LR; Manischewitz J; Coyle EM; Golding H Vaccine; 2014 Apr; 32(19):2188-97. PubMed ID: 24613520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]